1275 York AveNew York, NY 10065
Overview of Dr. Chapman
Dr. Paul Chapman is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian Brooklyn Methodist Hospital, Memorial Hospital for Cancer and allied Diseases, Memorial Hospital for Cancer and allied Diseases, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Weill Cornell Medicine and has been in practice 36 years. Dr. Chapman accepts several types of health insurance, listed below. He is one of 92 doctors at Memorial Hospital for Cancer and allied Diseases and one of 92 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterImmunology, 1984 - 1988
University of ChicagoResidency, Internal Medicine, 1981 - 1984
Weill Cornell MedicineClass of 1981
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 1988 - 2026
NJ State Medical License 2020 - 2025
IL State Medical License 1981 - 1984
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2017
- CMS Meaningful Use Stage Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2017
Clinical Trials
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 1997 Nov 01
- Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma Start of enrollment: 1998 May 01
- Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01
Publications & Presentations
PubMed
- Changing Role of Adjuvant Therapy in Stage III Melanoma.Paul B Chapman, Jedd D Wolchok
The New England Journal of Medicine. 2025-10-18 - Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.Neeta Pandit-Taskar, Audrey Mauguen, Denise Frosina, Achim Jungbluth, Klaus J Busam
Melanoma Research. 2025-10-01 - 4 citationsA phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.Christopher A Barker, Sandra P D'Angelo, Gloria Wasilewski, Alexa M Steckler, Ming Lian
Radiotherapy and Oncology. 2024-11-01
Press Mentions
Time's up for Anti-PD-1/L1 plus Targeted Therapy in BRAF MelanomaJanuary 26th, 2022
Merck’s Proposed Less Frequent Keytruda Dosing May Allow for Minor Uptake BoostNovember 19th, 2019
Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma PatientsJune 19th, 2019
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPOHealth Alliance PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Wellmark Alliance Select - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
